Promising drug aims to tame rare autoimmune attacks on the nervous system
NCT ID NCT07557420
First seen May 08, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study tests a drug called ravulizumab in 21 Chinese adults with a rare autoimmune disease called NMOSD, which causes severe attacks on the nerves and spinal cord. The goal is to see if the drug can reduce the number of relapses (flare-ups) and improve daily function. Participants will receive the drug by infusion and be monitored for safety and effectiveness over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.